BeOne Medicines (ONC) Net Equity Issued and Repurchased (2020 - 2021)
BeOne Medicines' (ONC) quarterly Net Equity Issued and Repurchased came in at $50000.0 in Q3 2021, down 100.0% year-on-year from $2.1 billion in Q3 2020, and down 100.0% on a QoQ basis from $2.1 billion in Q3 2020.
BeOne Medicines (ONC) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends
BeOne Medicines (ONC) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $50000.0 in Q3 2021.
- On a quarterly basis, Net Equity Issued and Repurchased fell 100.0% year-over-year to $50000.0 in Q3 2021; TTM through Dec 2022 was $50000.0, a 0.0% change from a year earlier, with the FY2021 full-year figure at $50.0 million, down 98.82% from the prior year.
- Net Equity Issued and Repurchased for Q3 2021 stood at $50000.0, down from $2.1 billion in the prior quarter.
- Over the last five years, Net Equity Issued and Repurchased for ONC reached as high as $2.2 billion in Q1 2020 and fell as low as $50000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 141.90 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 50,000.00 |
| Sep 30, 2021 | 50,000.00 |
| Sep 30, 2020 | 2.07 Bn |
| Sep 30, 2020 | 2.07 Bn |
| Mar 31, 2020 | 2.16 Bn |
| Mar 31, 2020 | 2.16 Bn |